Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 11 of 11 results for fluocinolone acetonide implant

  1. Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults.

    Technology appraisal guidance
    Published
    31 July 2019
    View recommendations

    Sections for TA590

  2. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.

    Technology appraisal guidance
    Published
    13 March 2024
    View recommendations

    Sections for TA953

  3. Faricimab for treating diabetic macular oedema (TA799)

    Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA799

  4. Brolucizumab for treating diabetic macular oedema (TA820)

    Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    31 August 2022
    View recommendations

    Sections for TA820

  5. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    14 September 2022
    View recommendations

    Sections for TA824

  6. Further research is recommended to resolve uncertainties about the cost effectiveness of fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema. This should focus on a group of patients whose condition is unresponsive to other available therapies, and include measures of efficacy and health-related quality of life. Research should focus on identifying appropriate utility values, taking into account the utility values for different levels of visual acuity and the relative relationship in utility values from treating the best-seeing and the worse-seeing eye. The appropriateness of generalising utility values from one group of eye conditions to another group would also be of value.

    resolve uncertainties about the cost effectiveness of fluocinolone acetonide intravitreal implant for the...

    Research recommendation
    Published
    9 June 2015

  7. Diabetic retinopathy: management and monitoring (NG242)

    This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.

    NICE guideline
    Published
    13 August 2024
    View recommendations

    Sections for NG242

  8. Taking a proportionate approach to technology appraisals

    Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.

  9. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.    

    Withdrawn guidance

  10. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (TA271)

    This guidance has been updated and replaced by NICE technology appraisal guidance 301.

    Withdrawn guidance

  11. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.

    Withdrawn guidance